Hypertrophic Cardiomyopathy: A Focus on Treatment, Specialty Medication Access, and the Impact of Clinical Pharmacy Programs
Join us for an in-depth exploration of hypertrophic cardiomyopathy (HCM), a complex and often underdiagnosed cardiac condition. This webinar will provide a comprehensive overview of HCM’s genetic and clinical landscape, highlight the evolving treatment pipeline, and examine the pharmacist’s critical role in optimizing patient outcomes. Attendees will gain valuable insights into specialty pharmacy considerations, FDA REMS requirements, and the impact of pharmacist-led management programs on safety and quality of care.
Learning Objectives
-
- Understand the epidemiology and pathophysiology of HCM, emphasizing genetic factors, phenotypic diversity, and age-related progression.
- Evaluate current and emerging therapies for HCM, including efficacy and safety data from pivotal clinical trials.
- Discuss key considerations for the specialty pharmacy, including barriers to medication access and factors impacting adherence.
- Review the FDA REMS requirements and evaluate the impact of pharmacist-led clinical management on safety, quality, and outcomes for patients on mavacamten.
Your Speakers
Carlee Montgomery, PharmD, CSP
Manager of Clinical Implementation
Kerry Mello-Parker, PharmD, MBA
Director, Rare Diseases and
REMS Programs
Anthony Orlando, PharmD, BSN, RN, CSP
Supervisor of Clinical Services
Missed the discussion?
We’ve got you covered! Watch the entire panel discussion below.
Additional Resources
Some content here?
Don't Miss the Next Webinar
Fill out the form below to get notified about any future Shields Webinars.
Fill out the form to be notified about any future Shields Webinars.